PP  Vol.5 No.2 , February 2014
Chronic Alcohol Consumption Affects Serum Enzymes Levels in the HIV-Infected Patients on Stavudine (d4T)/Lamivudine (3TC)/Nevirapine (NVP) Treatment Regimen
Abstract: Chronic alcohol use is a common problem globally among the HIV-infected patients on ARV treatment regimens, leading to severe liver damage and increase in serum enzymes. The study determined effect of chronic alcohol intake on serum enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyl transferase (GGT)) in HIV-infected patients on d4T/3TC/NVP treatment regimen in Uganda using the WHO alcohol use disorders’ identification test (AUDIT) tool and chronic alcohol use biomarkers (ALT, AST, GGT, AST/ALT ≥ 2.0 and mean corpuscular volume (MCV)). A case control study using repeated measure design with serial measurements model was used. Alcohol use biomarkers were used to standardize the gender differences in alcohol use. A total of 41 patients (21 alcohol group and 20 control group) were followed up for 9 months with blood sampling done at 3 month intervals. The serum enzymes’ levels were determined by using the Cobas Intergra 400 Plus analyzer system. The mean GGT levels were higher in chronic alcohol use group as compared to control group in both groups. The levels were above reference ranges during 6 month and three times higher during 9-month follow-up period for both chronic alcohol use self reporting WHO AUDIT tool and biomarkers’ groups. Generally, the mean AST, ALT and AST/ALT levels were slightly higher in alcohol use group as compared to control group and were slightly higher in both groups as compared to reference ranges during the 9 month follow-up period. Chronic alcohol consumption by HIV-infected patients on d4T/3TC/NVP drug regimen increased GGT and AST/ALT serum enzyme levels and hence was used as chronic alcohol use biomarkers.
Cite this paper: G. Bbosa, D. Kyegombe, W. Anokbonggo, A. Lubega, A. Mugisha and J. Ogwal-Okeng, "Chronic Alcohol Consumption Affects Serum Enzymes Levels in the HIV-Infected Patients on Stavudine (d4T)/Lamivudine (3TC)/Nevirapine (NVP) Treatment Regimen," Pharmacology & Pharmacy, Vol. 5 No. 2, 2014, pp. 181-194. doi: 10.4236/pp.2014.52025.

[1]   D. B. Heath, “Anthropology and Alcohol Studies: Current Issues,” Annual Reviews Anthropology, Vol. 16, 1987, pp. 99-120.

[2]   G. Micheal, “Alcohol Health Issues Related to Alcohol Consumption,” The Place of Alcohol in Human Culture, 1996, pp. 1-22.

[3]   Wikipedia, “Alcoholic Beverage,” Wikimedia Foundation Inc., St. Petersburg, 2009.

[4]   WHO, “Global Status Report on Alcohol 2004,” World Health Organization, Geneva, 2004.

[5]   WHO, “Alcohol and Mental Health,” World Health Organization, Regional Office for Europe, WHO European Ministerial Conference on Mental Health, Helsinki, 12-15 January 2005; Helsinki Conference Secretariat, Copenhagen, 2005.

[6]   WHO, “Alcohol and Injury in Emergency Department: Summary of the Report from the WHO Collaborative Study on Alcohol and Injuries,” WHO Library Cataloguing-in-Publication Data, 2007, pp. 1-11.

[7]   A. D. Johnson, “Female Alcohol Abuse Is a ‘Global Epidemic’,” New York Post, NYP Holdings, Inc., New York, 2013.

[8]   GENACIS, “Alcohol, Gender and Drinking Problems: Perspectives from Low and Middle Income Countries,” World Health Organization, Geneva, 2005, pp. 2-241.

[9]   J. Mbatia, R. Jenkins, N. Singleton and B. White, “Prevalence of Alcohol Consumption and Hazardous Drinking, Tobacco and Drug Use in Urban Tanzania, and Their Associated Risk Factors,” International Journal of Environmental Research and Public Health, Vol. 6, No. 7, 2009, pp. 1992-2003.

[10]   WHO-UNAIDS, “Global Adults and Children Estimated to Be Living with HIV in 2012 Report,” World Health Organization, UNAIDS, 2012.

[11]   UMoH, “Uganda AIDS Indicator Survey Report 2011,” Uganda Ministry of Health (UMoH), 2011.

[12]   A. Kafuko and P. Bukuluki, “Qualitative Research in Uganda on Knowledge, Attitude and Practices Concerning Alcohol, 2008,” USAID, Health Communication, YEAH and Afford: Corporate Agreement Number 617-A00-07-00005-00, 2008.

[13]   C. Lwanga-Ntale, “Drinking into Deeper Poverty: The New Frontier for Chronic Poverty in Uganda,” Chronic Poverty Research Center, Development Research and Training, Policy Brief No.1/2007, 2007.

[14]   I. S. Obot, “Alcohol Use and Related Problems in Sub-Saharan Africa,” African Journal of Drug and Alcohol Studies, Vol. 5, No. 1, 2006, pp. 17-25.

[15]   YEAH, “Alcohol Consumption in Uganda: Literature Review,” Young Empowered and Health-YEAH, 2007.

[16]   B. Neild, “Uganda Leads Its African Neighbors for Alcohol Intake: World’s 10 Best Drinking Nations,” Cable News Network (CNN) Report, 2013.

[17]   WHO, “Global Status Report on Alcohol and Health 2011,” World Health Organization Report, Geneva, 2011.

[18]   UNAIDS/WHO, “2007 AIDS Epidemic Update/Sub-Saharan Africa,” Joint United Nations Programme on HIV/ AIDS (UNAIDS), World Health Organization (WHO) 2007, 2008, p. 11.

[19]   WHO/UNICEF/UNAIDS, “Global HIV/AIDS Response: Epidemic Update and Health Sector Progress towards Universal Access, Progress Report 2011-2015,” World Health Organization HIV/AIDS Department, Geneva, 2011.

[20]   C. I. Ehlers, “Variations in ADH and ALDH in Southwest Calfornia Indians,” The Journal of the National Institute on Alcohol Abuse and Alcoholism, Vol. 30, No. 1, 2007, pp. 14-16.

[21]   M. Y. Eng, S. E. Luczak and T. L. Wall, “ALDH2, ADH1B and ADH1C Genotypes in Asians: A Literature Review,” The Journal of the National Institute on Alcohol Abuse and Alcoholism, Vol. 30, No. 1, 2007, pp. 22-26.

[22]   D. M. Scott and R. E. Taylor, “Health-Related Effects of Genetic Variations of Alcohol-Metabolizing Enzymes in African Americans,” The Journal of the National Institute on Alcohol Abuse and Alcoholism, Vol. 30, No. 1, 2007, pp. 18-20.

[23]   H. K. Seitz and P. Becker, “Alcohol Metabolism and Cancer Risk,” The Journal of the National Institute on Alcohol Abuse and Alcoholism, Vol. 30, No. 1, 2007, pp. 38-46.

[24]   S. Zakhari, “Overview: How Is Alcohol Metabolized by the Body?” The Journal of the National Institute on Alcohol Abuse and Alcoholism, Vol. 29, No. 4, 2006, pp. 245-252.

[25]   M. W. King, “Ethanol Metabolism,”, 2013.

[26]   K. S. Salmela, I. G. Kessova, I. B. Tsyrlov and C. S. Lieber, “Respective Roles of Human Cytochrome P-4502E1, 1A2 and 3A4 in the Hepatic Microsomal Ethanol Oxidizing System,” Alcoholism: Clinical and Experimental Research, Vol. 22, No. 9, 1998, pp. 2125-2132.

[27]   H. Joenje, “Metabolism: Alcohol, DNA and Disease,” Nature, Vol. 475, No. 7354, 2011, pp. 45-46.

[28]   C. S. Lieber, “Relationships between Nutrition, Alcohol Use, and Liver Disease,” National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2004.

[29]   C. Berr, F. Clavel-Chapelon, S. Dally, J. Daval, F. Fumeron, C. Girre, et al., “Alcohol Health Effects,” Inserm Centre of Collective Expertise, 2001, pp. 1-43.

[30]   M. Gurr, “Alcohol Health Issues Related to Alcohol Consumption,” 2nd Edition, International Life Sciences Institute (ILSI) Europe, Washington DC, 1996, pp. 1-18.

[31]   M. L. Ojeda, B. Vázquez, F. Nogales, M. Murillo and O. Carreras, “Ethanol Consumption by Wistar Rat Dams Affects Selenium Bioavailability and Antioxidant Balance in Their Progeny,” International Journal of Environmental Research and Public Health, Vol. 6, No. 8, 2009, pp. 2139-2149.

[32]   R. F. Butterworth, “Hepatic Encephalopathy: A Serious Complication of Alcoholic Liver Disease,” Alcohol Research & Health, Vol. 27, No. 2, 2003, pp. 143-145.

[33]   M. Bilban, S. Vrhovec and M. Z. Karlovsek, “Blood Biomarkers of Alcohol Abuse,” Archives of Industrial Hygiene and Toxicology, Vol. 54, 2003, pp. 253-259.

[34]   S. Kubota, N. Amino, Y. Matsumoto, N. Ikeda, S. Morita, T. Kudo, H. Ohye, E. Nishihara, M. Ito, S. Fukata and A. Miyauchi, “Serial Changes in Liver Function Tests in Patients with Thyrotoxicosis Induced by Graves’ Disease and Painless Thyroiditis,” Thyroid, Vol. 18, No. 3, 2008, pp. 283-287.

[35]   P. Mason, “Blood Tests Used to Investigate Liver, Thyroid or Kidney Function and Diseases,” The Pharmaceutical Journal, Vol. 272, 2004, pp. 446-448.

[36]   B. R. Thapa and A. Walia, “Liver Function Tests and Their Interpretations,” Indian Journal of Pediatrics, Vol. 74, No. 7, 2007, pp. 663-671.

[37]   E. W. Tiemersma, P. A. Wark, M. C. Ocke, A. Bunschoten, M. H. Otten, F. J. Kok and E. Kampman, “Alcohol Consumption, Alcohol Dehydrogenase 3 Polymorphism, and Colorectal Adenomas,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 12, No. 5, 2003, pp. 419-425.

[38]   C. P. Wild and R. Montesano, “A Model of Interaction: Aflatoxins and Hepatitis Viruses in Liver Cancer Aetiology and Prevention,” Cancer Letters, Vol. 286, No. 1, 2009, pp. 22-28.

[39]   J. W. Bennett and M. Klich, “Mycotoxins,” Clinical Microbiology Reviews, Vol. 16, No. 3, 2003, pp. 497-516.

[40]   M. C. Braude and H. M. Chao, “Genetic and Biological Markers in Drug Abuse and Alcoholism,” National Institute on Drug Abuse (NIDA) Research Monograph 66 1986. Department of Health and Human Service. Alcohol, Drug Abuse, and Mental Health Administration. Maryland, 1996, pp. 1-50.

[41]   K. M. Conigrave, L. J. Degenhardt, J. B. Whitfield, J. B. Saunders, A. Helander and B. Tabakoff, “CDT, GGT, and AST as Markers of Alcohol Use: The WHO/ISBRA Collaborative Project,” Alcoholism: Clinical and Experimental Research, Vol. 26, No. 3, 2002, pp. 332-338.

[42]   A. Helander, B. Tabakoff and WHO/ISBRA Study Centers, “Biochemical Markers of Alcohol Use and Abuse: Experience from the Pilot Study of the WHO/ISBRA Collaborative Project on State and Trait Markers of Alcohol,” Alcohol & Alcoholism, Vol. 32, No. 2, 1997, pp. 133-144.

[43]   Y. Littner and C. F. Bearer, “Detection of Alcohol Consumption during Pregnancy—Current and Future Biomarkers,” Elsevier publishers, Neuroscience and Biobehavioral Reviews, Vol. 31, No. 2, 2007, pp. 261-269.

[44]   SAMHSA, “The Role of Biomarkers in the Treatment of Alcohol Use Disorders,” US Center for substance Abuse Treatment Substance Abuse and Mental Health Service Administration, 2006.

[45]   T. F. Babor, J. C. Higgins-Biddle, J. B. Saunders and M. G. Monteiro, “The Alcohol Use Disorders Identification Test (AUDIT) Manual: Guidelines for Use in Primary Care,” 2nd Edition, Department of Mental Health and Substance Dependence, World Health Organization, 2001, pp. 4-32.

[46]   J. G. Bartlett and J. E. Gallant, “Medical Management of HIV Infection,” Johns Hopkins University School of Medicine, Johns Hopkins Medicine Health Publishing Business Group, Baltimore, 2006.

[47]   L. L. Brunton, J. S. Lazo and K. L. Parker, “Antiretroviral Agents and Treatment of HIV Infection,” Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 11th Edition, McGraw-Hill, New York, 2006, pp. 1273-1309.

[48]   G. Gómez-Moreno, J. Guardia, A. Cutando and J. Calvo-Guirado, “Pharmacological Interactions of Anti-Microbial Agents in Odontology,” Medicina Oral, Patología Oral y Cirugía Bucal, Vol. 14, No. 3, 2009, pp. E123-E128.

[49]   R. M. W. Hoetelmans, “Clinical Pharmacokinetics of Antiretroviral Drugs,” AIDS Reviews, Vol. 1, No. 3, 1999, pp. 167-178.

[50]   C. Hoffmann, J. K. Rockstroh and B. S. Kamps, “HIV Medicine 2007,” 15th Edition, Flying Publisher, 2007, Vol. 1, pp. 23-29.

[51]   C. F. Bearer, J. M. Stoler, J. D. Cook and S. J. Carpenter, “Biomarkers of Alcohol Use in Pregnancy,” Alcohol Research & Health, Vol. 28, No. 1, 2005, pp. 38-42.

[52]   S. K. Das, P. Nayak and D. M. Vasudevan, “Biochemical Markers for Alcohol Consumption,” Indian Journal of Clinical Biochemistry, Vol. 18, No. 2, 2003, pp. 111-118.

[53]   T. P. Dergisi, “The Diagnostic Validity of Screening Tests and Laboratory Markers in Alcohol Use Disorders,” Turkish Journal of Psychiatry, Vol. 16, No. 1, 2005, pp. 3-12.

[54]   J. J. Day and J. D. Sweatt, “Review of Epigenetic Mechanisms in Cognition,” Neuron, Vol. 70, No. 5, 2011, pp. 813-829.